NatWest Group plc Takes Position in Gilead Sciences, Inc. (NASDAQ:GILD)

NatWest Group plc bought a new position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) during the 4th quarter, Holdings Channel reports. The institutional investor bought 73,702 shares of the biopharmaceutical company’s stock, valued at approximately $6,808,000. Gilead Sciences comprises approximately 2.0% of NatWest Group plc’s portfolio, making the stock its 21st largest position.

Several other large investors have also recently bought and sold shares of GILD. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at approximately $25,000. HHM Wealth Advisors LLC lifted its stake in Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 154 shares during the last quarter. Valued Wealth Advisors LLC increased its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 161 shares during the last quarter. YANKCOM Partnership bought a new stake in shares of Gilead Sciences in the 4th quarter valued at about $28,000. Finally, Decker Retirement Planning Inc. acquired a new stake in Gilead Sciences in the 4th quarter valued at about $29,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

GILD has been the topic of several research analyst reports. Barclays upped their price objective on Gilead Sciences from $84.00 to $95.00 and gave the company an “equal weight” rating in a research note on Thursday, November 7th. Citigroup assumed coverage on Gilead Sciences in a report on Thursday, November 14th. They set a “buy” rating and a $125.00 price target for the company. Leerink Partners upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $74.00 to $96.00 in a report on Monday, October 21st. JPMorgan Chase & Co. raised their target price on shares of Gilead Sciences from $105.00 to $115.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 29th. Finally, Mizuho upped their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Thursday, November 21st. Eleven research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $98.39.

Insider Activity

In other Gilead Sciences news, Director Jeffrey Bluestone sold 6,788 shares of the stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $91.39, for a total value of $620,355.32. Following the completion of the transaction, the director now directly owns 8,920 shares in the company, valued at approximately $815,198.80. This trade represents a 43.21 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 142,180 shares of Gilead Sciences stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $97.22, for a total value of $13,822,739.60. Following the sale, the chief financial officer now directly owns 129,873 shares in the company, valued at $12,626,253.06. The trade was a 52.26 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 572,824 shares of company stock worth $53,611,715. Insiders own 0.29% of the company’s stock.

Gilead Sciences Stock Down 2.0 %

Shares of NASDAQ GILD opened at $96.04 on Friday. The stock has a 50-day moving average price of $92.97 and a two-hundred day moving average price of $86.49. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $100.51. The company has a current ratio of 1.26, a quick ratio of 1.10 and a debt-to-equity ratio of 1.24. The company has a market cap of $119.69 billion, a price-to-earnings ratio of 1,067.11, a PEG ratio of 1.37 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, beating the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm’s revenue was up 7.0% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.29 EPS. As a group, analysts forecast that Gilead Sciences, Inc. will post 4.34 earnings per share for the current fiscal year.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.